Filing summary
Entity and period: The supplied filing is Ziopharm Oncology, Inc.’s Form 10-K for the fiscal year ended December 31, 2018—not an Alaunos Therapeutics filing. The company described itself as a clinical-stage biopharmaceutical developer of cancer immunotherapies.
Business context and programs
Ziopharm’s two principal platforms were Sleeping Beauty, a non-viral approach to engineering T cells for CAR-T and personalized TCR therapies, and Controlled IL-12, a gene-delivery system intended to regulate IL-12 expression in tumors. The company had no approved products and no significant product revenue.
- Management expected a Phase 1 NCI trial of neoantigen-targeted TCR cells and a U.S. Phase 1 trial of rapid-manufactured CD19 CAR-T cells to begin in 2019.
- Controlled IL-12 trials included recurrent glioblastoma monotherapy and combinations with PD-1 inhibitors. A Phase 2 study with Regeneron’s Libtayo was planned for the first half of 2019.
- In a small Phase 1 subset of six recurrent glioblastoma patients receiving low-dose steroids and 20 mg veledimex, median overall survival was reported as 17.8 months, versus historical controls of five to eight months. This is preliminary, small-sample evidence, not a controlled comparison.
Financial results and liquidity
| Metric | FY 2018 | FY 2017 |
|---|---|---|
| Collaboration revenue | $0.146 million | $6.389 million |
| Research and development expense | $34.134 million | $45.084 million |
| General and administrative expense | $19.918 million | $14.798 million |
| Operating loss | $53.906 million | $53.493 million |
| Net loss | $53.117 million | $54.323 million |
| Net income (loss) applicable to common shareholders | $137.246 million | $(73.261) million |
| Net cash used in operating activities | $49.457 million | $54.669 million |
| Cash and cash equivalents at year-end | $61.729 million | $70.946 million |
Reported 2018 common-shareholder income was driven by a $207.361 million credit from settlement of a related-party relationship, not by operating profitability; the company still recorded a $53.117 million net loss. Operating expenses exceeded collaboration revenue, so a conventional operating margin is not meaningful. Working capital was $74.8 million, versus $69.9 million in 2017. Total liabilities were $9.487 million at year-end, and the balance sheet reported no debt balance. Management estimated existing cash would fund planned operations into the second quarter of 2020, while noting there were no committed additional financing sources.
Material changes and unusual items
- Revenue fell 98% year over year, primarily reflecting adoption of ASC 606, which changed the timing of revenue recognition under the Ares Trading arrangement. The company reported $146,000 of 2018 collaboration revenue under ASC 606; reported 2017 revenue was $6.389 million. The filing’s ASC 606 comparison indicates 2018 revenue would have been $4.878 million without adoption, so reported periods are not directly comparable.
- R&D expense declined 24%, mainly due to reduced preclinical and GvHD activity. G&A expense increased 35%, primarily from advisory and outside-service costs related to the Precigen license transaction and higher personnel costs.
- On October 5, 2018, Ziopharm entered a new exclusive license agreement with Precigen, replacing prior arrangements. Intrexon returned all Series 1 preferred stock, and Ziopharm’s obligations under the Ares Trading agreement were relieved. The transaction generated the $207.361 million accounting credit to accumulated deficit/common-shareholder income.
- The November 2018 private placement raised approximately $47.1 million net and issued 18.9 million common shares plus warrants for an additional 18.9 million shares at $3.01 per share. Potential dilution is therefore material.
- The FDA placed the planned third-generation CAR-T Phase 1 trial on clinical hold in June 2018, citing chemistry, manufacturing and controls information, including a minimum cell-viability threshold. Management expected to respond and begin treating patients in the second half of 2019.
Outlook, risks and contingencies
Management planned continued investment in clinical development and manufacturing capabilities, with several 2019 trial starts and potential Controlled IL-12 top-line data in 2020. These are forward-looking expectations, not assured milestones. The company anticipated continued losses and stated that failure to secure further capital or partnerships could require it to delay programs, reduce operations or prioritize among candidates.
- Key risks include clinical failure or results not replicated in larger studies, regulatory delays or additional FDA requirements, manufacturing and cell-viability challenges, and safety risks associated with engineered cell and gene therapies.
- The company relied on licensed intellectual property and third-party research, manufacturing and clinical collaborators. Precigen license terms include annual fees, potential milestone payments of up to $52.5 million for each licensed program, royalties and a share of sublicensing income.
- TriArm committed up to $35 million to the planned Eden BioCell joint venture for development in China, Taiwan and Korea; definitive agreements and closing were still expected in the first half of 2019.
- The filing disclosed $6.447 million in specified contractual obligations at December 31, 2018, including leases, the NCI CRADA and license fees. The company extended the CRADA in February 2019, adding a further $5 million commitment.
- No material legal proceedings were identified as of year-end. The auditor gave an unqualified opinion on the financial statements and internal control over financial reporting; management also concluded disclosure controls were effective.
Most important facts for investors to verify
- Confirm the issuer: the supplied filing is Ziopharm Oncology, Inc., despite the request metadata naming Alaunos Therapeutics, Inc.
- Assess cash burn, financing needs and the assumptions behind management’s estimated runway into Q2 2020, including subsequent financing or spending changes.
- Track resolution of the FDA clinical hold and the actual start, enrollment and results of planned CAR-T, TCR and Controlled IL-12 trials.
- Separate the $207.361 million non-operating settlement credit from recurring results; review the ASC 606 impact when comparing revenue across years.
- Evaluate dilution from the 18.9 million issued shares and 18.9 million warrants, plus any later share issuances or warrant exercises.
- Verify the status and funding terms of the Eden BioCell joint venture, the additional NCI CRADA commitment, and obligations under the Precigen license.